



Universiteit
Leiden
The Netherlands

Novel pharmaceutical interventions in experimental atherosclerosis and myocardial infarction

Hoorn, Johanna Wijnanda Anthonia van der

Citation

Hoorn, J. W. A. van der. (2008, October 30). *Novel pharmaceutical interventions in experimental atherosclerosis and myocardial infarction*. Retrieved from <https://hdl.handle.net/1887/13213>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13213>

Note: To cite this publication please use the final published version (if applicable).



3

**JWA van der Hoorn
W de Haan
JFP Berbée
LM Havekes
JW Jukema
PCN Rensen
HMG Princen**

**Niacin Increases HDL by
Reducing Hepatic
Expression and Plasma
Levels of Cholesteryl Ester
Transfer Protein in
APOE*3Leiden.CETP Mice**

Abstract

Objective: Niacin (nicotinic acid) potently decreases plasma triglycerides and LDL-cholesterol. In addition, niacin is also the most potent HDL-cholesterol increasing drug used in the clinic. In the present study, we aimed at elucidation of the mechanism underlying its HDL-raising effect.

Methods and Results: In APOE*3Leiden transgenic mice expressing the human CETP transgene, niacin dose-dependently decreased plasma triglycerides (up to -77%, $P<0.001$) and total cholesterol (up to -66%, $P<0.001$). At the same time, niacin dose-dependently increased HDL-cholesterol (up to +87%, $P<0.001$), plasma apoAI (up to +72%, $P<0.001$), as well as the HDL particle size. In contrast, in APOE*3Leiden mice that do not express CETP, niacin also decreased total cholesterol and TG but did not increase HDL-cholesterol. In fact, in APOE*3Leiden.CETP mice, niacin dose-dependently decreased the hepatic expression of CETP (up to -88%; $P<0.01$) as well as plasma CETP mass (up to -45%, $P<0.001$) and CETP activity (up to -52%, $P<0.001$). In addition, niacin dose-dependently decreased the clearance of apoAI from plasma and reduced the uptake of apoAI by the kidneys (up to -90%, $P<0.01$).

Conclusion: Niacin markedly increases HDL-cholesterol in APOE*3Leiden.CETP mice by reducing the CETP activity, as related to lower hepatic CETP expression and a reduced plasma (V)LDL pool, and increases HDL-apoAI by decreasing the clearance of apoAI from plasma.

Introduction

Dyslipidemia is an important risk factor for the development of cardiovascular disease (CVD). Although lowering of LDL-cholesterol (C) by e.g. statins reduces CVD risk by approximately 30%, substantial residual cardiovascular risk remains, even with very aggressive reductions in levels of LDL-C.¹⁻³ Due to clinical studies, which have shown that HDL-C, independently of LDL-C, is inversely correlated with the risk of CVD,^{4,5} attention has shifted toward strategies for targeting HDL composition as adjunctive therapy to prevent and treat CVD. Current strategies to mildly increase HDL-C levels include aggressive overall lifestyle modification (*i.e.* exercise, diet, weight loss, and smoking cessation), and modest increases in HDL-C levels are achieved with statins⁶ and fibrates (5-10%).⁷

Niacin (nicotinic acid, vitamin B3) has been described to exhibit lipid-modifying capacities already since the 1950s. Since then various (clinical) studies have shown the beneficial effects of niacin on plasma lipid levels. Treatment with niacin alone was associated with a 27% reduction in non-fatal myocardial infarction and it reduced all cause mortality by 11%.^{8,9} In combination with colestipol (FATS trial) or simvastatin (HATS trial), niacin reduced cardiac events by as much as 80-90%.^{10,11} These potent atherogenic properties of niacin are thought to be due to its marked HDL-elevating effect (+20% to +30%), besides its potent effect on reducing plasma TG (-40% to -50%) and LDL-C (-20%).^{7,12} In fact, niacin is currently the most effective therapy for elevating HDL-C.

The mechanism underlying the ability of niacin to reduce the plasma (V)LDL level has been well-studied. By selective binding to GPR109A on adipocytes, niacin suppresses hormone sensitive triglyceride lipase (HSL) activity, resulting in a decreased release of free fatty acids (FFA) from adipose tissue and decreased plasma FFA levels.¹³ The resulting reduced supply of FFA towards the liver is believed to bring about a decreased hepatic VLDL-TG production, resulting in reduced VLDL-TG and (V)LDL-C levels.^{13,14} In contrast, the mechanism underlying the HDL-C raising effect of niacin has not been elucidated as yet. This is probably related to the lack of suitable animal models that respond in a human-like manner to HDL-raising drug interventions. In wild-type mice and apoE-knockout mice (the classical animal model for hyperlipidemia and atherosclerosis), rats and dogs, niacin only transiently reduced plasma levels of TG but failed to raise HDL-C.^{15,16} An HDL-C-elevating effect of niacin has been reported in rabbits, but with 30% ethanol as dosing vehicle and only after 12 weeks of treatment.¹⁷

Therefore, the aim of this study was to elucidate the mechanism underlying the HDL-C raising effect of niacin. To this end, we used our recently developed APOE*3Leiden (E3L).CETP transgenic mouse model. We have previously demonstrated that E3L mice have a human-like lipoprotein profile in which the elevated plasma cholesterol and TG levels are mainly confined to the (V)LDL-sized lipoprotein

fractions.^{18,19} These mice develop atherosclerosis upon dietary cholesterol feeding and respond in a human-like manner to drugs used in the treatment of CVD (e.g. statins, fibrates, cholesterol uptake inhibitors, calcium channel blockers and angiotensin II receptor antagonists²⁰⁻²³), but they did not yet respond to HDL-modulating interventions. By cross-breeding E3L mice with mice expressing human CETP under control of its natural flanking regions, E3L.CETP were obtained²⁴ that respond to the HDL-raising effects of fenofibrate,²⁵ atorvastatin²⁶ and torcetrapib.²⁷ We now fed these mice a Western-type diet without or with increasing doses of niacin to reveal the mechanism underlying its HDL-C raising effect.

Methods

Animals

Hemizygous human CETP transgenic (CETP) mice, expressing a human CETP minigene under the control of its natural flanking sequences²⁸ were purchased from the Jackson Laboratory (Bar Harbor, ME) and crossbred with hemizygous *E3L* mice¹⁸ at our Institutional Animal Facility to obtain E3L and E3L.CETP littermates.²⁴ In this study, female mice were used, housed under standard conditions in conventional cages with free access to food and water. At the age of 12 weeks, E3L and E3L.CETP mice were fed a semi-synthetic cholesterol-rich diet, containing 15% (w/w) fat and 0.25% (*E3L*) or 0.1% (E3L.CETP) (w/w) cholesterol (Western-type diet; Hope Farms, Woerden, The Netherlands) for three weeks to obtain similar total cholesterol levels in both strains (about 12-14 mmol/L). After matching based on total plasma cholesterol (TC), triglyceride (TG) levels, and age, mice (n=8 per group) received a Western-type diet without or with 0.03% (~36 mg/kg/day), 0.1% (~118 mg/kg/day), 0.3% (~360 mg/kg/day) or 1% (~1180 mg/kg/day) niacin (Sigma, St. Louis, MO, USA) for at least 3 weeks. These doses correspond well to the doses used in humans, if the 10 times faster metabolism of mice as compared to humans is taken into account. Experiments were performed after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 am, unless indicated otherwise. The institutional Ethical Committee on Animal Care and Experimentation has approved all experiments.

Plasma lipid and lipoprotein analysis

Plasma was obtained via tail vein bleeding as described²⁴ and assayed for TC, TG and phospholipids (PL), using the commercially available enzymatic kits 236691 and 11488872 (Roche Molecular Biochemicals, Indianapolis, IN, USA) and 'Phospholipids B' (InstruChemie, The Netherlands), respectively. The distribution of lipids over plasma lipoproteins was determined by fast-performance liquid chromatography (FPLC) using a Superose 6 column as described previously.²⁴ HDL-C was isolated by precipitating the

apoB-containing lipoproteins from 20 μ L EDTA plasma by adding 10 μ L heparin (LEO Pharma, The Netherlands; 500 U/mL) and 10 μ L 0.2 M $MnCl_2$. Mixtures were incubated for 20 min at room temperature and centrifuged for 15 min at 13,000 rpm at 4°C. In the supernatant HDL-C was measured using enzymatic kit 236691 (Roche Molecular Biochemicals, Indianapolis, IN, USA).

Plasma apoAI concentration

Plasma apoAI concentrations were determined using a sandwich ELISA. Here to, rabbit anti-mouse apoAI polyclonal antibody (ab20453; Abcam plc, Cambridge, UK) was coated overnight onto Costar strips (Costar, Inc., New York, NY) (at 3 μ g/mL) at 4°C and incubated with diluted mouse plasma (dilution 1:400,000) for 90 min at 37°C. Subsequently, goat anti-mouse apoAI antibody (600-101-196; Rockland Immunochemicals, Inc., Gilbertsville, PA; dilution 1:3000) was added and incubated for 90 min at 37°C. Finally, horse radish peroxidase (HRP)-conjugated rabbit anti-goat IgG antibody (605-4313; Rockland; dilution 1:15000) was added and incubated for 90 min at 37°C. HRP was detected by incubation with tetramethylbenzidine (Organon Teknika, Boxtel, The Netherlands) for 15 min at room temperature. Purified mouse apoAI (A23100m; Biodesign International, Saco, Maine, USA) was used as a standard.

HDL size by native PAGE

The HDL size was determined essentially as described.²⁹ Total lipoproteins were isolated from plasma by ultracentrifugation (5 h at 541,000 g) as the $d < 1.21$ g/mL plasma fraction in a TLA 100.3 rotor (Beckman). Lipoproteins (7.5 μ g protein) were loaded onto a 4-20% polyacrylamide Tris.HCl gel (BioRad, Hercules, CA, USA) and electrophoresis was performed according to the manufacturer's protocol. Gels were stained with Coomassie Brilliant Blue (Merck) and HDL size was compared with globular protein standards (HMW native marker kit, GE Healthcare).

Plasma lipolysis

Post-heparin plasma from overnight fasted mice was collected from the tail vein at 20 minutes after intraperitoneal injection of heparin (1.0 U/g body weight). Post-heparin plasma triacylglycerol hydrolase activity was determined in the presence or absence of 1 mol/L NaCl to estimate the hepatic lipase (HL) activity, which was calculated as the portion of total triacylglycerol hydrolase activity not inhibited by 1 mol/L NaCl.³⁰

Preparation of ¹²⁵I-apoAI-labeled autologous HDL

ApoAI was radiolabeled at pH 10 with carrier-free ¹²⁵I according to the ICI method³¹, and separated from unbound ¹²⁵I by Sephadex G50 gel filtration. ¹²⁵I-apoAI (~75 μ g) was incubated with 1.4 mL of plasma from E3L.CETP mice (3 h at 37°C), and ¹²⁵I-apoAI-HDL

was isolated after density gradient ultracentrifugation. The specific activity was ~15 cpm /ng HDL protein.

In vivo kinetics of ¹²⁵I-apoAI-labeled HDL

E3L.CETP mice were injected via the tail vein with ¹²⁵I-apoAI-HDL (40 µg protein) in a total volume of 200 µL PBS. At the indicated time points after injection, blood was collected from the tail vein to determine the plasma decay of ¹²⁵I-apoAI. The total plasma volumes of the mice were calculated from the equation $V \text{ (mL)} = 0.04706 \times \text{body weight (g)}$, as determined from previous ¹²⁵I-BSA clearance studies.³² At 6 h after injection, the mice were sacrificed and organs were taken and counted for ¹²⁵I-activity. Values were corrected for serum radioactivity present in the liver (84.7 µL/g wet weight), kidneys (135.2 µL/g wet weight), skeletal muscle (13.7 µL/g wet weight) and white adipose tissue (16.1 µL/g wet weight).³³

Hepatic lipid analysis

Liver tissue samples were homogenized in phosphate-buffered saline (approx. 10% wet w/v), and the protein content was measured according to the method of Lowry *et al.* Lipids were extracted, separated by high-performance thin-layer chromatography on silica gel plates and analyzed with TINA2.09 software (Raytest Isotopen Messgeräte, Straubenhardt, Germany), as described before.³⁴

Hepatic mRNA expression

Total RNA extraction from liver tissue samples was performed using RNA-Bee (Amsbio, Oxon, UK) according to the manufacturer's instructions. RNA was converted to single-stranded cDNA by a reverse transcription procedure (Promega) according to the manufacturer's protocol using random primers. cDNA levels were measured by real-time polymerase chain reaction (PCR) using the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. PCR master mix from Eurogentec was used. Primers and probes were obtained from Biosource (Nivelles, Belgium). The probes were labelled with 3-BHQ1 and 5-FAM or 5-TET. The mRNA levels were normalized to mRNA levels of three housekeeping genes (*i.e.*, cyclophilin, HPRT and GAPDH). Primers and probes used for this study were described previously.²⁵ The level of mRNA expression for each gene of interest was calculated according to the manufacturer's instructions (Applied Biosystems) as described previously.³⁵

CETP mass and activity in plasma

Plasma CETP mass was analyzed by ELISA using kit 'CETP ELISA Daiichi' (Daiichi Pure Chemicals Co, Ltd, Tokyo, Japan). Plasma CETP activity was measured as the transfer of

[³H]cholesteryl oleate ([³H]CO) from exogenous LDL to HDL as described.³⁶ CETP activity was calculated as μmol CE transfer per mL plasma per hour.

Biliary lipid secretion

The common bile duct of anesthetized mice was ligated, the gall bladder was cannulated, and bile was collected during 90 minutes.³⁰ Cholesterol, PL and total bile acids in bile were determined using kits '236691' (Roche Molecular Biochemicals, Indianapolis, IN, USA), 'Phospholipids B' (Instruchemie, The Netherlands) and 'Total bile acids assay' (Bio-Stat, UK), respectively.

Fecal excretion of bile acids and neutral sterols

The mice were housed at 3 mice per cage. Feces produced during 2 subsequent periods (48 h each) were separated from the wood shavings by sieving. Aliquots of lyophilized feces were used for determination of neutral and acidic sterol content by gas-liquid-chromatography procedures as described.³⁰

Statistical analysis

All data are presented as means ± SD unless indicated otherwise. Data were analyzed parametrically by one-way ANOVA followed by Dunnett to correct for multiple testing. *P*-values less than 0.05 were considered statistically significant. SPSS 14.0 was used for statistical analysis.

Results




Figure 1. Effect of niacin on lipoprotein profiles. E3L (A) and E3L.CETP (B) mice received a Western-type diet without (open circles) or with (closed circles) niacin (118 mg/kg/day) for 3 weeks. Plasma was pooled per group and the distribution of cholesterol over the individual lipoproteins was determined after separation by FPLC.




Figure 2. Dose-dependent effect of niacin on plasma triglycerides and total cholesterol. E3L.CETP mice received a Western-type diet without or supplemented with incremental doses of niacin for 3 weeks. Plasma triglycerides (A) and total cholesterol (B) were determined. Values are means \pm SD (n=8 per group). * P <0.05, ** P <0.01, *** P <0.001.


effects of niacin on plasma TG and TC levels were dose-dependent as shown in **figure 2**. At the highest dose of 1180 mg/kg/day, niacin reduced TG levels by -77% (P <0.001) (**figure 2A**) and TC levels by -66% (P <0.001) (**figure 2B**).

The HDL-increasing effect of niacin in E3L.CETP mice is dose-dependent

To investigate whether the HDL-increasing effect of niacin in E3L.CETP mice was also dose-dependent, we determined HDL-C concentrations in whole plasma after precipitation of apoB-containing lipoproteins by heparin/ MnCl₂. Indeed, niacin appeared to decrease (V)LDL-C levels up to -79% (P <0.001) (**figure 3A**), and to increase HDL-C up to +87% (P <0.001) (**figure 3B**), both in a dose-dependent fashion. We next evaluated whether niacin also affects apoAI, the main apolipoprotein constituent of HDL.

Niacin decreases plasma lipids in both E3L and E3L.CETP mice, but increases HDL only in E3L.CETP mice

No adverse clinical signs were observed with increasing dosages of niacin as indicated by absence of differences in weight gain and plasma ALT levels between treatment groups and the control. Treatment of E3L mice with niacin (118 mg/kg/day) caused a sustained reduction in plasma TG by -26% (1.4 ± 0.6 mM vs 1.9 ± 0.6 mM; P <0.05) and in plasma TC by -35% (9.2 ± 3.4 mM vs 14.2 ± 4.5 mM; P <0.05). Lipoprotein fractionation by FPLC showed that the reduction in cholesterol was confined to the apoB-containing lipoproteins (V)LDL, whereas HDL-C was not affected (**figure 1A**). An equal dose of niacin even more potently reduced plasma TG (-57%, P <0.05) and TC (-44%, P <0.01) in E3L.CETP mice. As in E3L mice, the TC-decreasing effect of niacin in E3L.CETP mice was caused by a reduction of (V)LDL-C. However, whereas niacin did not affect HDL levels in E3L mice, it increased HDL-C in E3L.CETP mice (**figure 1B**). In E3L.CETP mice, the



Indeed, niacin dose-dependently increased apoAI up to +72% ($P<0.001$) (figure 3C). Whereas niacin thus increases both HDL-C and apoAI, the effects on HDL-C at the various doses are somewhat more pronounced than on apoAI, suggesting that niacin increases the lipidation of apoAI. This was reflected by a modest increase of the HDL particle size as determined by native PAGE (figure 4). Further analyses of the pooled HDL fractions showed a decrease in triglycerides (-45%) and an increase in cholesteryl ester (+56%) and phospholipids (+66%) (data not shown). Niacin did not seem to affect the hepatic synthesis or clearance of HDL, at least judged from unchanged hepatic mRNA expression of genes involved in HDL synthesis (*apoA1*, *abca1*) or clearance (*sr-b1*) (data not shown). Hepatic *pltp* mRNA expression was slightly increased upon niacin treatment (data not shown). In plasma niacin did decrease the HL activity, albeit that the effect was not dose-dependent (maximal reduction of -47% at 118 mg/kg/day; $P<0.05$).

Niacin increases the residence time of apoAI in plasma

To evaluate whether the dose- dependently increased plasma apoAI level as induced by niacin-treatment was caused by decreased clearance of apoAI from plasma, we determined the effect of niacin on the plasma kinetics of intravenously injected ¹²⁵I-apoAI-labeled HDL (figure 5). Indeed, niacin dose-dependently increased the residence of ¹²⁵I-apoAI in plasma (figure 5A). From the mono-exponential decay curves it was calculated that the plasma half-life of ¹²⁵I-apoAI (3.5±0.1 h) was increased by niacin at 118 mg/kg/day (5.5±1.3 h; $P<0.01$) and 1180 mg/kg/day (6.6±1.3 h; $P<0.01$). This was




Figure 4. Dose-dependent effect of niacin on the HDL particle size. Total lipoproteins from pooled plasma were subjected to native 4-20% PAGE, and the resulting gel was stained with Coomassie Brilliant Blue.

accompanied by a dose-dependent reduction in the uptake of ^{125}I -activity by the liver (up to -50%; $P<0.05$) and the kidneys (up to -90%; $P<0.01$) (**figure 5B**). For comparison, the uptake of ^3H cholesteryl oleoyl ether-labeled HDL by the liver was much larger (approx. 40% of dose/g wet weight), whereas the uptake by the kidneys was undetectable (data not shown).

Niacin reduces the hepatic lipid content

The effects of niacin on plasma lipid metabolism in E3L.CETP mice are consistent with a niacin-induced reduction in CETP activity. Since CETP expression is regulated by the hepatic

cholesterol content,²⁸ we first examined effects of niacin on liver lipids (**figure 6A**). Niacin decreased the hepatic TG content (-38%, $P<0.05$). This is consistent with the inhibitory effects of niacin on HSL in adipose tissue,¹³ thereby reducing the trafficking of FFA to the liver for TG synthesis. Niacin also decreased the hepatic TC content (-21%, $P<0.01$), which was mainly attributed to a reduction in hepatic cholesteryl esters (-22%, $P<0.05$). This effect was in line with a compensatory increase in hepatic *Hmgcoared* mRNA expression (+232%, $P<0.05$) (not shown).




Figure 5. Dose-dependent effect of niacin on plasma apoAI kinetics. E3L.CETP mice were injected with ^{125}I -apoAI-HDL, and plasma ^{125}I activity was determined at the indicated time points (A). After the last time point, mice were sacrificed and ^{125}I activity was determined in the liver, kidneys, skeletal (hindlimb) muscle and white adipose tissue (WAT) (B). n=5 per group. * $P<0.05$, ** $P<0.01$.




Figure 6. Effect of niacin on hepatic lipid content and *CETP* mRNA expression. E3L.CETP mice received a Western-type diet without (open bars) or with (closed bars) niacin for 3 weeks, and livers were excised. Total lipids were extracted, and triglycerides (TG), total cholesterol (TC), free cholesterol (FC) and cholesteryl esters (CE) were separated by high-performance thin-layer chromatography and quantified (A). Total RNA was extracted, and *CETP* mRNA expression was measured by RT-PCR (B). Values are means \pm SD (n=7 per group). * P <0.05, ** P <0.01.

Niacin decreases hepatic CETP mRNA expression and plasma CETP levels

The decrease in hepatic cholesterol was indeed accompanied by a dose-dependent reduction in hepatic *CETP* mRNA up to -88% (P <0.01) at 1180 mg/kg/day (**figure 6B**). To evaluate whether the niacin-induced decreased hepatic *CETP* mRNA expression was reflected by reduced *CETP* levels in plasma, we determined both *CETP* mass (**figure 7A**) and activity (**figure 7B**). Indeed, niacin dose-dependently decreased plasma *CETP* mass and *CETP* activity to a similar extent (up to -45% and -52%; P <0.001).

Niacin does not affect biliary and fecal cholesterol output

To evaluate the consequences of the niacin-induced alterations in lipid metabolism on lipid excretion into bile and feces, we determined bile flow, biliary lipids and sterols in stool. Niacin did not affect bile flow or the bile composition (cholesterol, phospholipids and bile acids). The highest dose of niacin (1180 mg/kg/day) did affect the composition of the fecal sterols to some extent, as reflected by a slight non-significant increase in neutral sterols and a decrease in bile acids (-22%; P <0.05). However, like the dietary input, total fecal sterol output was not affected by niacin (**table 1**).

Discussion

In this study, we investigated the mechanism(s) underlying the HDL-raising effect of niacin. We demonstrated that *CETP* plays a crucial role in the niacin-induced increase in plasma HDL-C and apoA1 levels in E3L.CETP mice. Niacin reduced *CETP* dependent transfer of cholesterol from HDL to (V)LDL as related to lower hepatic *CETP* expression

	Control	Niacin 118 mg/kg/d	Niacin 1180 mg/kg/d
<i>Bile</i>			
Bile flow (μL/min/100g bw)	2.0 ± 0.5	2.0 ± 0.4	2.3 ± 0.7
Bile acid output (nmol/min/100g bw)	50 ± 14	67 ± 18	65 ± 25
Cholesterol output (nmol/min/100g bw)	1.1 ± 0.3	1.1 ± 0.2	1.1 ± 0.2
Phospholipid output (nmol/min/100g bw)	14 ± 3	14 ± 3	16 ± 5
<i>Feces</i>			
Neutral sterols (μmol/100g bw/d)	32.7 ± 2.2	34.8 ± 4.6	36.1 ± 4.5
Bile acids (μmol/100g bw/d)	8.6 ± 1.5	8.4 ± 1.6	6.7 ± 0.9*
Total sterols (μmol/100g bw/d)	41.3 ± 3.1	43.2 ± 5.1	42.7 ± 4.7

Table 1. Effect of niacin on biliary and fecal lipid output. *E3L.CETP* mice received a Western-type diet without or supplemented with niacin for 3 weeks. The bile bladder was cannulated, and bile flow and composition were measured during 90 minutes (n=6-7). Feces were collected per cage (3 mice per cage) in two subsequent periods of 48 h each (n=8). Fecal composition was measured by gas-liquid-chromatography and fecal sterol output was calculated. Data are presented as mean ± SD, *P<0.05.

and a reduced plasma (V)LDL pool. This resulted in an increased lipidation of apoA1, as reflected by an increased HDL particle size, and a reduced uptake of apoA1 by the kidneys.

We previously showed that *E3L* mice are highly susceptible to dietary interventions with respect to modulating plasma lipid levels and that these mice show a human-like response to drug interventions aimed at treatment of CVD (e.g. statins, fibrates, cholesterol uptake inhibitors, calcium channel blockers and angiotensin II receptor antagonists²⁰⁻²³) with respect to alterations in the lipoprotein profile and/or atherosclerosis development. This is in sheer contrast with wild-type *C57Bl/6* mice and conventional hyperlipidemic mice, such as apoE-deficient or LDL receptor-deficient mice, which show either an adverse response or no response to such interventions.³⁷ In




Figure 7. Dose-dependent effect of niacin on plasma CETP mass and activity. *E3L.CETP* mice received a Western-type diet without or supplemented with incremental doses of niacin for 3 weeks. Plasma CETP mass (A) and CETP activity (B) were determined. Values are means ± SD (n=8 per group). *P<0.05, ***P<0.001.

particular, administration of niacin to wild-type mice or apoE-deficient mice did show a transient decrease in plasma TG and FFA levels, but failed to increase plasma HDL-C in these mice.^{13,16} Likewise, we now showed that niacin lowered TG and cholesterol within apoB-containing lipoproteins in E3L mice, but did not affect HDL-C levels.

Recently, we showed that introduction of the human CETP gene in *E3L* mice results in a mouse model which also shows a human-like response with regard to raising HDL-C after treatment with fenofibrate,²⁵ atorvastatin²⁶ and torcetrapib.²⁷ Since the introduction of CETP permits cross-talk between (V)LDL and HDL metabolism via the exchange of neutral lipids, we reasoned that the E3L.CETP mouse would also be an excellent mouse model to study the effects of niacin on HDL metabolism.

First, we observed that niacin dose-dependently reduced VLDL-TG and (V)LDL-C levels. The primary action of niacin is inhibition of HSL activity in adipose tissue after binding to the GPR109A receptor that is selectively expressed by adipocytes. This results in a decreased liberation of FFA from adipose tissue, and a decreased flux of albumin-bound FA to the liver, which is required for substrate-driven hepatic TG synthesis and VLDL production.¹³ As a consequence we thus observed a concentration-dependent drop in VLDL-TG and (V)LDL-C levels. In addition, we observed that niacin reduced the hepatic cholesterol content. This may be caused by reduced input of cholesterol from plasma into the liver, since plasma (V)LDL-C concentrations are reduced and cholesterol-enriched HDL is formed from which cholesteryl esters are presumably not being delivered efficiently to the liver. The decreased hepatic cholesterol content cannot be explained by differences in biliary sterol output, since the excretion of bile acids and cholesterol remained unchanged. Alternatively, niacin may reduce the endogenous hepatic synthesis of cholesterol.

Second, we showed that niacin dose-dependently raised HDL-C levels in E3L.CETP mice, but not in E3L mice, as paralleled by a less pronounced raise in apoA1. The presence of CETP thus plays a crucial role in the HDL-raising effect of niacin, and we reasoned that niacin may dose-dependently inhibit CETP activity. It is well-known that VLDL-TG is a driving force for CETP activity, and the relative proportions of VLDL and HDL have been shown to play a determinant role in CETP activity. It has been demonstrated that the capacity of apoB-containing lipoproteins to accept CE from HDL is closely correlated with the relative TG content of the lipoprotein acceptor particles.³⁸⁻⁴¹ By decreasing VLDL levels, niacin may thus reduce CETP activity simply by decreasing the availability of VLDL-TG as substrate for CETP.

Our data corroborate recent observations from Hernandez *et al.*^{15,42} who showed that niacin increased HDL-C levels in CETP mice and APOB.CETP mice, but not their CETP-deficient wild-type littermates. In fact, they speculated the reduced VLDL levels to be the main mechanism underlying the HDL-raising effect of niacin. However, we observed that niacin not only reduced plasma CETP activity, but also dose-dependently reduced plasma CETP mass to a similar extent, suggesting that niacin reduces the

synthesis of CETP leading to less CETP protein being released in plasma as reflected by similar reductions in CETP mass and activity. Indeed, niacin dose-dependently reduced hepatic *CETP* mRNA expression. It has been reported that hepatic cholesterol determines the hepatic *CETP* mRNA expression in CETP transgenic mice,²⁸ presumably via an LXR responsive element in the CETP promoter.⁴³ Therefore, it is likely that niacin decreases the hepatic CETP mRNA expression as a result of the observed decreased cholesterol content of the liver upon niacin treatment.

Besides increasing HDL-C, niacin also dose-dependently increased plasma apoAI levels. Niacin has been shown to inhibit the uptake of HDL-apoAI (but not HDL-CE) by cultured hepatocytes,⁴⁴ which we now confirmed *in vivo*. This may partly contribute to the increased apoAI levels. Such a potential effect of niacin should be independent of GPR109A, since expression of this receptor has not been detected in hepatocytes.^{13,45,46} Together with our observations that hepatic mRNA expression of genes involved in HDL synthesis (*apoA1*, *acba1*) and clearance (*sr-b1*) were not affected by niacin, and an increase of PLTP would rather lead to a decrease in HDL-C levels^{30,47}, it is most likely that the raise in apoAI is explained directly by the niacin-induced decreased CETP activity, which prevents cholesteryl ester transfer from HDL to (V)LDL. This leads to increased lipidation of apoAI, resulting in larger and cholesteryl ester-enriched HDL particles, and thus decreased glomerular filtration and excretion of lipid-poor apoAI via the cubulin/megalin receptor complex.⁴⁸ Indeed, we demonstrated a clear dose-dependent reduction in the uptake of ¹²⁵I-apoAI by the kidney.

Based on our collective data, we thus propose the following mechanism by which niacin reduces TG and (V)LDL-C and concomitantly raises HDL-C, as summarized in **figure 8**. By inhibiting HSL in adipose tissue upon binding of the niacin receptor GPR109A, niacin decreases TG lipolysis and thereby the supply of FFA to the liver, required for lipid synthesis. The consequently reduced hepatic lipid content results in a lower VLDL production and thus lower (V)LDL levels. In addition, reduction in hepatic cholesterol results in reduced hepatic expression of CETP, as well as diminished release of CETP into the plasma. Additionally, HL activity is reduced which may contribute to reduced remodelling of HDL in plasma, resulting in decreased clearance of HDL. The HDL particles become CE enriched, and less lipid-poor apoAI is cleared by the kidney. Niacin thus increases HDL-C and apoAI levels by 1) reducing levels of (V)LDL, the acceptor of CETP-mediated HDL-CE transfer, 2) decreasing CETP expression, 3) decreasing HL activity, and 4) decreasing the clearance of apoAI.

As concluded from a many clinical trials using statins, lowering LDL-C alone is not longer regarded to be sufficient to treat CVD. Therefore, comprehensive lipid management, in which raising HDL-C is an important target, is becoming a new standard.^{4,7} Niacin (at dosages of 2-4 g/day) is unsurpassed in raising HDL-C. We show that niacin (in a clinical relevant range if we take into account the 5-10 times faster metabolism of mice) significantly improves the plasma lipid levels in E3L.CETP mice, *e.g.*




Figure 8. Proposed mechanism underlying the HDL-raising effect of niacin. For explanation see text. CE, cholesteryl ester; FA, fatty acids; HSL, hormone sensitive lipase; TC, total cholesterol; TG, triglycerides.

reduces TG and (V)LDL-C and increases HDL-C, albeit that total fecal sterol output is unaffected. Whether this will lead to improved HDL function and HDL-related reductions in CVD in the clinic still remains to be investigated.

Niacin has not been a very successful drug thus far because of its side-effect: severe flushing. Niacin is nowadays produced as an extended release (ER) compound, which enhances the tolerability. Clinical trails AIM-HIGH⁴⁹ and

ARBITER-6 (HALTS)⁵⁰ evaluating the secondary prevention of CVD by ER niacin treatment are currently running. Post-hoc analysis of a subgroup of ARBITER-2, a randomized, placebo-controlled trial, showed increases in HDL-C upon daily intake of ER niacin (+20%), which were related to reduced progression of carotid intima-media thickness in the setting of both normal glycemic status and diabetes mellitus.^{51,52} Since the flushing effects of niacin appeared to be prostaglandin D₂ (PGD₂) receptor mediated,⁵³ a combination therapy is currently being evaluated combining ER niacin and PGD₂ receptor antagonist laropiprant, which is better tolerated than ER niacin alone.⁵⁴ Currently one trail evaluating effects of this combination drug on hard clinical endpoints, as myocardial infarction, stroke or revascularisation (HPS2-THRIVE) is underway.

In conclusion, our results show that niacin increases HDL-C by reducing the hepatic *CETP* expression and plasma CETP protein and CE transfer activity in *E3L.CETP* mice. Therefore, we postulate that reduction of *CETP* expression contributes to the

increase in HDL that is found in human subjects treated with niacin, which should be subject of further investigation.

Acknowledgements

We thank M.E.A. Bekkers, R. van den Hoogen, A. van Nieuwkoop, E.H. Offerman and M. Voskuilen for their excellent technical assistance.

Sources of Funding

This work was supported by the Leiden University Medical Center (Gisela Thier Fellowship to P.C.N.R.), the Netherlands Organization for Scientific Research (NWO grant 908-02-097 and NWO VIDI grant 917.36.351 to P.C.N.R.; NWO grant 903-39-291 to L.M.H.), the Netherlands Heart Foundation (NHS grant 2003B136 to P.C.N.R.), and the Center for Medical Systems Biology (project 115 to L.M.H.). J.W.J. is an established clinical investigator of the Netherlands Heart Foundation (2001 D032).

Disclosures

None.

References

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-1504.
2. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;352:1425-1435.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267-1278.
4. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. *Curr Med Res Opin* 2004;20:1253-1268.
5. Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. *N Engl J Med* 1989;321:1311-1316.
6. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. *JAMA* 2007;297:499-508.
7. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. *JAMA* 2007;298:786-798.
8. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. *J Intern Med* 2005;258:94-114.
9. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. *J Am Coll Cardiol* 2005;45:185-197.
10. Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. *Am J Cardiol* 2006;98:1542-1549.

11. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345:1583-1592.
12. Rader DJ. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. *Am J Cardiol* 2003;91:18E-23E.
13. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. *Nat Med* 2003;9:352-355.
14. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. *Acta Med Scand* 1963;173:719-722.
15. Krause BR, Princen HM. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? *Atherosclerosis* 1998;140:15-24.
16. Declercq V, Yeganeh B, Moshtaghi-Kashanian GR, Khademi H, Bahadori B, Moghadasian MH. Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. *J Cardiovasc Pharmacol* 2005;46:18-24.
17. Parwaresch MR, Haacke H, Mader C. Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds. *Atherosclerosis* 1978;31:395-401.
18. Van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, de Bruijn I, van Vlijmen B, van der Boom H, Havekes LM, Frants RR. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. *J Biol Chem* 1993;268:10540-10545.
19. Van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, Frants RR, Hofker MH, Havekes LM. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. *J Clin Invest* 1994;93:1403-1410.
20. Delsing DJ, Offerman EH, van Duyvenvoorde W, van der Boom H, de Wit EC, Gijbels MJ, Van der Laarse A, Jukema JW, Havekes LM, Princen HM. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. *Circulation* 2001;103:1778-1786.
21. Delsing DJ, Jukema JW, Van de Wiel MA, Emeis JJ, Van der Laarse A, Havekes LM, Princen HM. Differential Effects of Amlodipine and Atorvastatin Treatment and Their Combination on Atherosclerosis in ApoE*3-Leiden Transgenic Mice. *J Cardiovasc Pharmacol* 2003;42:63-70.
22. Kooistra T, Verschuren L, de Vries-Van der Weij, Koenig W, Toet K, Princen HM, Kleemann R. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. *Arterioscler Thromb Vasc Biol* 2006;26:2322-2330.
23. Van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. *J Hypertens* 2007;25:2454-2462.
24. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. *Arterioscler Thromb Vasc Biol* 2006;26:2552-2559.
25. Van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HM, Jukema JW, Havekes LM, Rensen PC. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. *J Lipid Res* 2007;48:1763-1771.
26. De Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, Romijn JA, Jukema JW, Havekes LM, Rensen PC. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. *Atherosclerosis* 2008;197:57-63.
27. De Haan W, de Vries-Van der Weij, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. *Circulation* 2008;117:2515-2522.
28. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. *J Clin Invest* 1992;90:1290-1295.
29. Gautier T, Masson D, Jong MC, Pais de Barros JP, Duverneuil L, Le GN, Deckert V, Dumont L, Bataille A, Zak Z, Jiang XC, Havekes LM, Lagrost L. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. *Biochem J* 2005;385:189-195.

30. Post SM, De Crom R, Van Haperen R, Van Tol A, Princen HM. Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. *Arterioscler Thromb Vasc Biol* 2003;23:892-897.
31. McFarlane AS. Efficient trace-labelling of proteins with iodine. *Nature* 1958;182:53.
32. Jong MC, Rensen PC, Dahlmans VE, Van der Boom H, Van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. *J Lipid Res* 2001;42:1578-1585.
33. Rensen PC, Herijgers N, Netscher MH, Meskers SC, Van Eck M, Van Berkel TJ. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. *J Lipid Res* 1997;38:1070-1084.
34. Post SM, De Roos B, Vermeulen M, Afman L, Jong MC, Dahlmans VE, Havekes LM, Stellaard F, Katan MB, Princen HM. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis. *Arterioscler Thromb Vasc Biol* 2000;20:1551-1556.
35. Post SM, Groenendijk M, Solaas K, Rensen PC, Princen HM. Cholesterol 7 α -hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. *Arterioscler Thromb Vasc Biol* 2004;24:768-774.
36. Speijer H, Groener JE, van RE, van TA. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. *Atherosclerosis* 1991;90:159-168.
37. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij, Van der Hoorn JW, Princen HM, Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. *Arterioscler Thromb Vasc Biol* 2007;27:1706-1721.
38. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. *J Clin Invest* 1991;88:2059-2066.
39. Marzetta CA, Meyers TJ, Albers JJ. Lipid transfer protein-mediated distribution of HDL-derived cholesteryl esters among plasma apo B-containing lipoprotein subpopulations. *Arterioscler Thromb* 1993;13:834-841.
40. Guerin M, Dolphin PJ, Chapman MJ. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. *Arterioscler Thromb* 1994;14:679-685.
41. Guerin M, Dolphin PJ, Chapman MJ. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. *Arterioscler Thromb* 1994;14:199-206.
42. Hernandez M, Wright SD, Cai TQ. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. *Biochem Biophys Res Commun* 2007;355:1075-1080.
43. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. *J Clin Invest* 2000;105:513-520.
44. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. *Arterioscler Thromb Vasc Biol* 1997;17:2020-2028.
45. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB. Molecular identification of high and low affinity receptors for nicotinic acid. *J Biol Chem* 2003;278:9869-9874.
46. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi K. Molecular identification of nicotinic acid receptor. *Biochem Biophys Res Commun* 2003;303:364-369.
47. Ehnholm S, Van Dijk KW, Van 't Hof B, Van der Zee A, Olkkonen VM, Jauhiainen M, Hofker M, Havekes L, Ehnholm C. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. *J Lipid Res* 1998;39:1248-1253.
48. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. *J Clin Invest* 2006;116:3090-3100.
49. Windler E, Schoffauer M, Zyriax BC. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. *Diab Vasc Dis Res* 2007;4:136-142.
50. Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). *Cardiovasc Drugs Ther* 2007;21:221-225.

51. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation* 2004;110:3512-3517.
52. Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. *Vasc Health Risk Manag* 2007;3:159-164.
53. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, Moers A, Pfeffer K, Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. *J Clin Invest* 2005;115:3634-3640.
54. Lai E, De Lepeleire I, Crumley TM, Liu F, Wenning LA, Michiels N, Vets E, O'neill G, Wagner JA, Gottesdiener K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. *Clin Pharmacol Ther* 2007;81:849-857.

